Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVM-1118 + Nivolumab in Advanced Hepatocellular Carcinoma
NCT05257590Phase 2Recruiting
- Sponsor
- TaiRx, Inc.
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in hepatocellular carcinoma (HCC), sponsored by TaiRx, Inc.. Started May 2022; status: recruiting.
02
Drugs
dasatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05257590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05257590.